Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Immucell Corp changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 26 | 30 | +4 |
| Shares | 982.1K | 1.06M | +74.9K (+7.6%) |
| Value | $5.41M | $5.42M | +$16.5K (+0.3%) |
New holders (4)
Institutions that held Immucell Corp at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Empire Financial Management Company, LLC | 42,000 | $214.6K | 0.09% |
| Citadel Advisors LLC | 16,962 | $87.4K | 0.00% |
| Prosperity Planning, Inc. | 16,000 | $81.8K | 0.04% |
| FMR LLC | 1 | $5 | 0.00% |
Sold out (0)
Institutions that held Immucell Corp at the end of Q4 2022 and filed for Q1 2023 without it.
None.